Hofseth Biocare ASA

As of June 30, 2026, Hofseth Biocare ASA carries a market capitalization of 673.29M, placing it among publicly traded companies globally. Its enterprise value stands at 903.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hofseth Biocare ASA has 506.23M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.26, and the price-to-book ratio stands at -21.92.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 903.22M versus a market cap of 673.29M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hofseth Biocare ASA maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,078.17, indicating conservative leverage, while an interest coverage ratio of -2.66 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -33.56, reflecting losses generated across the asset base. The company generates approximately 2.94M in revenue per employee across its workforce of 82.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.49 indicates how many times Hofseth Biocare ASA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hofseth Biocare ASA recorded 182,000.00 in income tax expense. The company reported a pretax loss of -136.37M and -136.55M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 20, 2026, Hofseth Biocare ASA's stock has declined approximately 26.88% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Hofseth Biocare ASA generated 242.20M in revenue and converted that into -136.55M in net income, yielding earnings per share of -0.32. EBITDA reached -73.45M, while operating income came in at -114.48M.

As of June 30, 2026, Hofseth Biocare ASA holds 107.98M in cash and equivalents against 338.60M in total debt, resulting in a net debt position of 109.12M. Total book value stands at -30.71M, with working capital of -36.70M providing operational flexibility.

Hofseth Biocare ASA produced 13.60M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -34.66M in capital expenditures, free cash flow totaled -21.06M - equivalent to -0.05 per share.

Over the twelve months ended June 30, 2026, Hofseth Biocare ASA posted a gross margin of 37.37, reflecting its pricing power and cost economics. The operating margin of -47.27 and net profit margin of -56.38 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.29, meaning Hofseth Biocare ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hofseth Biocare ASA's most recent stock split took place on October 16, 2020.